Mitigating the Bfl-1-mediated antiapoptotic pathway in diffuse large B cell lymphoma by inhibiting HDACs
S.-S. Yoon, E. Park, C. Lee, J. Park, J. Liu, J. Hong, D.-Y. Shin, J. M. Byun, H. Yun, Y. Koh
Abstract
The authors have withdrawn their manuscript whilst they perform additional experiments to test some of their conclusions further. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Systems biology-enabled targeting of NF-κB and BCL2 overcomes microenvironment-mediated BH3-mimetic resistance in DLBCL.
Aimilia Vareli, Haripriya Vaidehi Narayanan, … Simon A. Mitchell·Cell Death and DiseasePeer-reviewed·Aug 16, 2025
- Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition
R. Winkler, A.-S. Mägdefrau, … C. Kosan·OncogenePeer-reviewed·Sep 6, 2022
- Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphoma
Calixte Calaud, Emilio M. Serrano-López, … Pilar M. Domínguez·Blood NeoplasiaPeer-reviewed·Mar 2, 2026
- DuoHexaBody-CD37 induces direct cytotoxic signaling in diffuse large B-cell lymphoma
Simar Pal Singh, Kumar Mangalam, … Annemiek B. van Spriel·eLifePeer-reviewed·Jul 20, 2026
- Distinct Response Patterns to PHB Modulators in B Cell Lymphoma Models
Christoph Schultheiß, Maja Kadel, … Mascha Binder·bioRxiv·Jun 12, 2025
- HDAC1 acts as tumor suppressor in ALK-positive anaplastic large-cell lymphoma: Implications for HDAC inhibitor therapy
Maša Zrimšek, Kristina Draganić, … Gerda Egger·LeukemiaPeer-reviewed·Apr 2, 2025